mRNA Flu Vaccine Shows Stronger, Longer-Lasting Immune Response
Moderna is developing an mRNA-based influenza vaccine that aims to provide broader and more durable protection than traditional flu shots. Clinical trials suggest the vaccine expands the immune system's antibody response, potentially reducing hospitalizations and deaths.
Why it matters
This represents a significant technological shift in preventative medicine that could improve public health outcomes by mitigating the impact of vaccine strain mismatches.
Flu shots reduce hospitalizations and deaths for the roughly one billion people worldwide that get the flu each year. But they are less effective when the vaccine strains don’t closely match the viruses circulating in the community. Today’s vaccines are made months in advance of the flu season due to a long manufacturing process. When projections are off, strain mismatch can reduce the efficacy of the flu vaccines from about 60% (in a good year) down to 19%. A broader immune response could translate to a more effective vaccine even when the virus is changing faster than vaccine makers can update their shots.
The article reports on scientific findings and clinical trial data without political or ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in